Related Articles
Lipoprotein(a) and recurrent atherosclerotic cardiovascular events: the US Family Heart Database
AbstractBackground and Aims. Higher levels of lipoprotein(a) drive increasing risk of atherosclerotic cardiovascular disease (ASCVD) in otherwise healthy i
‘Pretty aggravating’: Town’s water supply turns pink, making it undrinkable for residents
A water tower malfunction is causing headaches in an Iowa town.
Oncodetect Test Is Now Available for MRD Detection in Solid Tumors
The Oncodetect test is now available for use in molecular residual disease detection in patients with solid tumors.
Breaking the Silence: Europe Unites Against Alcohol Harm
AMSTERDAM — Today, the EU launched a new coalition of health organizations and experts to advocate for the reduction of alcohol-related illnesses, injuries, and deaths…
Rally for Research: California Scientists Support SB 829
Please click the link to complete this form.
A Doctor’s Science-Backed Formula for Aging Better
Dr. Eric Topol’s research revealed it’s not so much genes that lead to long life but instead simple and practical steps to stay healthy. He’s…
Coexistence of a fluid responsive state and venous congestion signals in critically ill patients: a multicenter observational proof-of-concept study – Critical Care
Background Current recommendations support guiding fluid resuscitation through the assessment of fluid responsiveness. Recently, the concept of fluid tolerance and the prevention of venous congestion…
Replacement as an aging intervention
Nature Aging – Lore et al. explore how biological and synthetic replacement therapies, from engineered tissues to advanced prosthetics, could restore aging cells and organs,…
Poised to Reshape Treatment Landscape: The Phase 3 Clinical Trial of Disitamab Vedotin as a First-Line Therapy for HER2-Expressing Locally Advanced or Metastatic Urothelial Carcinoma Reached its Primary Endpoints of PFS and OS
/PRNewswire/ — On May 12th, 2025, RemeGen Co., Ltd. (“RemeGen”, stock symbols: 688331.SH/09995.HK) announced that its phase 3 clinical trial (Study ID:…
